Cros

Trialjectory Grows Pharmaceutical and Biotech Clinical Trial Partnerships by 800 Percent

Retrieved on: 
Monday, December 5, 2022

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Trialjectory ("the Company"), an AI-powered decision support platform that democratizes patient access to advanced cancer treatments and empowers the pharmaceutical and biotech industry to execute more patient-centric clinical trials, announced today it is currently working with more than 50 pharmaceutical companies, emerging biotechs and Contract Research Organizations to develop and execute clinical trials that focus more on patients' unique medical and personal needs – an increase of 800 percent since the beginning of 2020.

Key Points: 
  • With more than 3 million treatment matches to date, Trialjectory has grown its database from 2,000 clinical trials in 2019 to over 20,000 trials in 2022.
  • "The first step toward increasing all enrollment in clinical studies is to address the fears and myths about what it means to participate in a clinical trial.
  • "Since partnering with Trialjectory, MPNRF has accelerated clinical trial access for patients living with myeloproliferative neoplasms (MPN).
  • Working directly with patients, healthcare providers and pharmaceutical companies, Trialjectory democratizes access to advanced cancer treatment and empowers the pharmaceutical and biotech industry to execute more patient-centric clinical trials.

The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency

Retrieved on: 
Thursday, December 1, 2022

BRACKNELL, England, Dec. 1, 2022 /PRNewswire/ -- As the conversation around hybrid and decentralised clinical trials (DCT) moves from why to how, sponsors are increasingly seeking the best ways to embed the new model into their routine workflows.

Key Points: 
  • "Despite each of these service providers being dependent on the other to do their job, there is often no direct line of contact between the two.
  • Instead, the shared client becomes the key liaison for both, impairing effective communication, draining clinical trial efficiency, and placing additional burden on the sponsor."
  • The group will consider how the absence of communication between central laboratories and mobile health providers can contribute to inefficiencies, lead to duplicated efforts, and put data quality at risk.
  • Leveraging our next generation technologies, we deliver agile and precise services designed to meet the diverse needs of our clients.

Bank Chief Risk Officers Under Increasing Pressure as Recession Looms

Retrieved on: 
Thursday, December 1, 2022

PHILADELPHIA and NEW YORK, Dec. 1, 2022 /PRNewswire/ -- Chief Risk Officers are balancing a wide range of demands heading into 2023 – a year in which many emerging risks may be realized, the CRO Outlook 2023 study by the Risk Management Association and global management consultancy Oliver Wyman has found. In addition, North American bank CROs representing institutions with assets ranging from $25 billion to over $1 trillion say economic worries and the need to prepare for potential recession are piling on top of non-financial risks like consumer compliance, cyber threats, and climate risk.

Key Points: 
  • Climate and ESG risk also remain high on the CRO risk agenda.
  • "At RMA, we are focused on supporting Bank CROs and all financial risk professionals as macroeconomic headwinds create further challenges," RMA President and CEO Nancy Foster said.
  • "Risk officers have their fingers on the pulse of threats to their companies' success and on opportunities that lie in change.
  • RMA promotes an enterprise approach to risk management that focuses on credit risk, market risk, and operational risk.

The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency

Retrieved on: 
Thursday, December 1, 2022

BRACKNELL, England, Dec. 1, 2022 /PRNewswire/ -- As the conversation around hybrid and decentralised clinical trials (DCT) moves from why to how, sponsors are increasingly seeking the best ways to embed the new model into their routine workflows.

Key Points: 
  • "Despite each of these service providers being dependent on the other to do their job, there is often no direct line of contact between the two.
  • Instead, the shared client becomes the key liaison for both, impairing effective communication, draining clinical trial efficiency, and placing additional burden on the sponsor."
  • The group will consider how the absence of communication between central laboratories and mobile health providers can contribute to inefficiencies, lead to duplicated efforts, and put data quality at risk.
  • Leveraging our next generation technologies, we deliver agile and precise services designed to meet the diverse needs of our clients.

Global 3D Protein Structure Analysis Markets Report 2022-2032: Advancements in Equipment for Protein Structure Analysis and An Increase in R&D Expenditure to Accelerate Protein Structure Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022

In 2021, the global 3D protein structure analysis market was valued at $1,017.2 million, and it is expected to reach $2,676.6 million by 2032, growing at a CAGR of 9.32% during the forecast period 2022-2032

Key Points: 
  • In 2021, the global 3D protein structure analysis market was valued at $1,017.2 million, and it is expected to reach $2,676.6 million by 2032, growing at a CAGR of 9.32% during the forecast period 2022-2032
    The growth in the global 3D protein structure analysis market is expected to be driven by technological advancements in equipment for protein structure analysis and by an increase in R&D expenditure to accelerate protein structure analysis.
  • Leading manufacturers like Bruker Corporation, JEOL Ltd., and Spectris plc provide equipment for 3D protein structure analysis according to one's needs.
  • Based on product, the global 3D protein structure analysis market is expected to be dominated by the consumable segment.
  • The presence of major equipment providers of 3D protein structure analysis has a major impact on the market.

GHO Capital invests in Sapio Sciences, a leading, high growth lab informatics platform company

Retrieved on: 
Thursday, December 1, 2022

The business is optimally positioned in a high growth market where many incumbent solutions are not fit for purpose.

Key Points: 
  • The business is optimally positioned in a high growth market where many incumbent solutions are not fit for purpose.
  • GHOs support and investment will allow Sapio to explore multiple avenues for growth and expansion for the company, product offering and global footprint.
  • The Partners at GHO Capital, said, The trend towards adopting lab informatics solutions is accelerating.
  • Sapio provides LIMS, ELN, and Scientific Data Management Solutions through its flexible, scalable, and easy-to-use Seamless Informatics Platform.

CenExel CNS Opens Center in Los Alamitos, California

Retrieved on: 
Wednesday, November 30, 2022

Los Alamitos, California, Nov. 30, 2022 (GLOBE NEWSWIRE) -- CenExel CNS announces the grand opening of the newest clinical research facility in Los Alamitos, California.

Key Points: 
  • Los Alamitos, California, Nov. 30, 2022 (GLOBE NEWSWIRE) -- CenExel CNS announces the grand opening of the newest clinical research facility in Los Alamitos, California.
  • CenExel CNS has been operating clinical research centers in the area since 2000, and this site will be the largest, with 20,000+ square feet, more than 80 beds, and state-of-the-art equipment throughout.
  • The CenExel CNS Los Alamitos site will be led by Chief Clinical Officer David Walling, PhD, and Chief Operating Officer Dalia Botros, MD.
  • The CenExel Centers of Excellence deliver the engagement, expertise, and results to ensure that their clients achieve their clinical research goals.

CRISPR and Cas Genes Market Report 2022: Growing Need For Novel Therapeutics Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 30, 2022

The global CRISPR and Cas genes market size is expected to reach USD 9.6 billion by 2030.

Key Points: 
  • The global CRISPR and Cas genes market size is expected to reach USD 9.6 billion by 2030.
  • The market is expected to register a CAGR of 17.9% during the forecast period, owing to the increasing usage of CRISPR and Cas genes systems in the biomedical research field.
  • In January 2020, Mammoth Biosciences raised USD 45 million to develop next-gen CRISPR products for therapeutics & diagnostics purposes.
  • Chapter 3 Crispr & Cas Genes Market Variables, Trends And Scope
    Chapter 7 Market Categorization: Regional Estimates & Trend Analysis by Product, Application & End-use

Dr. Ravi Karra Joins Advanced Clinical to Accelerate Global Growth and Deliver Innovative Oncology Trials

Retrieved on: 
Wednesday, November 30, 2022

Advanced Clinical, a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey, is pleased to announce that Dr. Ravi Karra has been appointed Vice President, Oncology.

Key Points: 
  • Advanced Clinical, a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey, is pleased to announce that Dr. Ravi Karra has been appointed Vice President, Oncology.
  • He has been actively involved in innovative trial designs that utilize translational research data including molecular and imaging biomarkers.
  • As we continue to expand internationally, we are excited to have Dr. Karra join our team as we seek to deliver more innovative oncology trials and elevate our strategy as leaders in oncology trial development," said Julie Ross, President and CEO of Advanced Clinical.
  • Advanced Clinical is a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey.

Vial: Faster, Better, Cheaper CRO Powered by Technology, Announces Series B led by General Catalyst

Retrieved on: 
Wednesday, November 30, 2022

Together the teams collaborated on building a technology platform that drives efficiencies in every step of a clinical trial.

Key Points: 
  • Together the teams collaborated on building a technology platform that drives efficiencies in every step of a clinical trial.
  • Vial's Technology Platform is made up of three key platforms: Site Startup platform, eSource platform and Patient Recruiting platform.
  • Vial is the CRO sponsors can trust to be a true partner and deliver for their clinical trials.
  • Vial operates across multiple therapeutic areas ( Dermatology CRO , Ophthalmology CRO , Oncology CRO , Gastroenterology CRO , Neurology CRO , and Cardiology CRO ).